Conclusion
These results confirm the tolerable safety profile of LXS196. The encouraging clinical activity demonstrated provides evidence that targeting the PKC pathway in MUM should be explored and supports the continued evaluation of LXS196 in combination with other targeted therapies. LXS196, now known as darovasertib (IDE196), is currently being explored by Ideaya biosciences in doublet combinations with the MEK inhibitor binimetinib and the cMET inhibitor crizotinib (NCT03947385).